<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121667">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518842</url>
  </required_header>
  <id_info>
    <org_study_id>Siqueira Research Center</org_study_id>
    <nct_id>NCT01518842</nct_id>
  </id_info>
  <brief_title>Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy</brief_title>
  <acronym>RetinaCell</acronym>
  <official_title>Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the behavior of the intravitreal use of bone marrow derived stem
      cells in patients with ischemic retinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the effects on visual acuity, electroretinography, fluorescein angiography and
      optical coherence tomography in 30 patients with ischemic retinopathy, including diabetic
      retinopathy with severe loss of retinal capillaries undergoing intravitreal injection of
      bone marrow derived stem cells.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in size of FAZ at 48 weeks</measure>
    <time_frame>1 day to 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in central foveal thickness and best corrected visual acuity at 48 weeks</measure>
    <time_frame>1 day to 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>test group intravitreal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label study of Ischemic Retinopathy patients with best-corrected visual acuity (BCVA) worse than 20/200.
Intervention: Biological: intravitreal injection of autologous bone marrow stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravitreal Bone Marrow Stem Cells</intervention_name>
    <description>One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.</description>
    <arm_group_label>test group intravitreal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of Ischemic Retinopathy

          -  Enlargement of foveal avascular zone-FAZ (ischaemia or capillary drop out of &gt;30% on
             Fluorescein retinography

          -  logarithm of minimum angle of resolution (logMAR) BCVA of 1.0 (Snellen equivalent,
             20/200) or worse

          -  Able (in the Investigator's opinion) and willing to comply with all study
             requirements

        Exclusion Criteria:

          -  previous ocular surgery other than cataract

          -  presence of cataract or other media opacity that would influence ocular fundus
             documentation and adequate ERG and visual field evaluation

          -  other ophthalmic disease like glaucoma and uveitis

          -  previous history of blood disorders like leukemia

          -  known allergy to fluorescein or indocyanine green
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rubens C Siqueira, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rubens Siqueira Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rubens C Siqueira, MD,PhD</last_name>
    <phone>55(17)32345858</phone>
    <email>rubenssiqueira@terra.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rubens Siqueira Research Center</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15010-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rubens c Siqueira, mD,PhD</last_name>
      <phone>55(17)32140896</phone>
      <email>rubenssiqueira@terra.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 12, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Rubens Camargo Siqueira</investigator_full_name>
    <investigator_title>MD,PhD - Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ischemic retinopathy, stem cell,bone marrow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
